CONVERGENCE BIO
LIVE

Serial Number

98576548

Owner

Convergence Bio, Inc.

Attorney

Ryan S. Hilbert

Filing Date

May 30, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CONVERGENCE BIO Trademark

Serial Number: 98576548

CONVERGENCE BIO is a trademark filed by Convergence Bio, Inc. on May 30, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Convergence Bio, Inc. (2 trademarks)

800 Boylston St, Ste 2222
Boston, MA 02199

Entity Type: 03

Trademark Details

Filing Date

May 30, 2024

Registration Date

Not Registered

Published for Opposition

May 26, 2026

Goods & Services

pharmaceutical preparations, vaccines, and medical therapeutic pharmaceuticals for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; medical therapeutics in the form of medicines and medical preparations for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines, and medical therapeutic pharmaceuticals for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; medical therapeutics in the form of medicines and medical preparations for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; vaccines for human use; pharmaceutical preparations, vaccines, and medical therapeutic pharmaceuticals for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; medical therapeutics in the form of medicines and medical preparations for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss

research and development services in the field of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development services of new pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals relating to therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; research and development of new pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals relating to therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; development of pharmaceutical preparations, vaccines and medicines; medical research for development of therapeutic modalities for treatment of diseases; pharmaceutical, vaccine, medical therapeutic, and medical therapeutic pharmaceutical drug development and discovery; clinical studies in the nature of medical research services and conducting clinical trials for others; clinical studies, namely, clinical research in the field of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; preclinical and clinical development of therapeutic products, namely, development of medicines, pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals

assays and reagents for use in scientific and biomedical research

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 26, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 26, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 20, 2026 NONP
EXPARTE APPEAL TERMINATED
May 19, 2026 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 29, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 29, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 29, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 29, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 29, 2026 CNEA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 27, 2026 ERFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 27, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 27, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 27, 2026 REAP
EX PARTE APPEAL-INSTITUTED
Apr 27, 2026 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Apr 27, 2026 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Apr 27, 2026 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 27, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 27, 2026 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 27, 2025 GNFN
FINAL REFUSAL E-MAILED
Oct 27, 2025 GNFR
FINAL REFUSAL WRITTEN
Oct 27, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 2, 2025 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 2, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 2, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 2, 2025 REAP
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 5, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 5, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 2, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 2, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 2, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 12, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2024 NWOS
NEW APPLICATION ENTERED
May 30, 2024 NWAP